What is Biocytogen Pharmaceuticals (Beijing) Co Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Biocytogen Pharmaceuticals (Beijing) Co Enterprise Value Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend
Dec20
Dec21
Dec22
Dec23
Enterprise Value
-
-
10,030.78
4,924.79
Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value Distribution in the Biotechnology Industry
* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value falls into.
Biocytogen Pharmaceuticals (Beijing) Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBIT for today is
Biocytogen Pharmaceuticals (Beijing) Co's current Enterprise Value is HK$6,509.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-306.6 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBITDA for today is:
Biocytogen Pharmaceuticals (Beijing) Co's current Enterprise Value is HK$6,509.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-306.6 Mil.
Biocytogen Pharmaceuticals (Beijing) Co's current Enterprise Value is HK$6,509.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$784.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co Enterprise Value Related Terms
Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Business Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02315 has been successfully added to your